Huntington's disease Nicotinamide Vitamin Brain-derived neurotrophic factor Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Histone deacetylase inhibitor Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by an expansion of the polyglutamine (polyQ) repeat in exon-1 in the Huntingtin gene (HTT). This results in misfolding and accumulation of the huntingtin (htt) protein, forming nuclear and cytoplasmic inclusions. HD is associated with dysregulation of gene expression as well as mitochondrial dysfunction. We hypothesized that by improving transcriptional regulation of genes necessary for energy metabolism, the HD motor phenotype would also improve. We therefore examined the protective effects of nicotinamide (NAM), a well-characterized water-soluble B vitamin that is an inhibitor of sirtuin1/class III NAD + -dependent histone deacetylase (HDAC). In this study, both mini-osmotic pumps and drinking water deliveries were tested at 250 mg NAM/kg/day, using the B6.HDR6/1 transgenic mouse model. Results were similar for both modes of delivery, and there was no evidence of toxicity. We found that NAM treatment increased mRNA levels of brain-derived neurotrophic factor (BDNF), and Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), the master regulator of mitochondrial biogenesis. Protein levels of BDNF were also significantly increased. In addition, NAM treatment increased PGC-1α activation in HD mice, pointing to a possible mode of action as a therapeutic. Critically, NAM treatment was able to improve motor deficits associated with the HD phenotype, tested as time courses of open field, rotarod, and balance beam activities. These improvements were substantial, despite the fact that NAM did not appear to reduce htt aggregation, or to prevent late-stage weight loss. Our study therefore concludes that NAM or similar drugs may be beneficial in clinical treatment of the motor dysfunctions of HD, while additional therapeutic approaches must be added to combat the aggregation phenotype and overall physiological decline.
Introduction
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor dysfunction, emotional disturbances, cognitive dysfunction, weight loss, and premature death. HD is caused by an expansion of a trinucleotide (CAG)n repeat in the coding sequence of the huntingtin (HTT) gene on chromosome-4, resulting in an expanded polyglutamine (polyQ) tract in huntingtin (htt), with the age of onset inversely correlated with repeat number (Duyao et al., 1993) . HD, along with Alzheimer's disease, Parkinson's disease (PD), spinal cerebellar ataxia, and prion-based dementia, is classified as a misfolded protein disorder, based on the characteristic intranuclear and cytoplasmic pathogenic aggregations of truncated and full-length htt protein observed in human patients and in mouse models of HD (Davies et al., 1997; DiFiglia et al., 1997) . The HDR6/1 transgenic mouse model contains human huntingtin gene exon-1 under the control of the endogenous promoter, with approximately 115 CAG repeats. In this model, overt neurological symptoms similar to human HD become evident at 15-21 weeks of age, with premature death occurring at 32-40 weeks (Mangiarini et al., 1996) . Behavioral abnormalities have been documented as early as 4 weeks of age (Bolivar et al., 2004) .
Altered transcription of genes involved in cellular processes vital to neuronal function and survival has been demonstrated in mouse and human HD (Luthi-Carter et al., 2000; Zuccato et al., 2001 Zuccato et al., , 2003 suggesting a direction for therapies. Acetylation and deacetylation of histones play an important role in regulation of chromatin condensation and gene transcription (Roth et al., 2001) ; therefore, increasing histone acetyltransferase activity, through inhibition of the histone deacetylases (HDACs), has been used as a strategy to slow the progression of many neurological disorders. The efficacy of HDAC inhibition in HD was first observed in a Drosophila model (Steffan Neurobiology of Disease 41 (2011) 43-50 
